DICE方案治疗难治和复发性非霍奇金淋巴瘤的疗效分析  

Efficacy of DICE (Dexamethasone, Etoposide, Ifosfamide, and Cisplatin) Regimen on Recurrent and Refractory Non-Hodgkin's Lymphoma

作　　者：薄兰君[1] 梁爱斌[1] 刘班[1] 陈毓华[1] 王菲[1] 金雪萍[1] 

机构地区：[1]同济大学附属同济医院血液科,上海200065

出　　处：《癌症》2006年第12期1553-1556,共4页Chinese Journal of Cancer

基　　金：上海市卫生局科技发展基金(No.01451)~~

摘　　要：背景与目的:目前对于难治性和复发性非霍奇金淋巴瘤(non-Hodgkin)slymphoma,NHL)尚无标准解救化疗方案,本文旨在探讨DICE方案(地塞米松,异环磷酰胺,顺铂及VP-16)治疗难治和复发性NHL的疗效和不良反应。方法:80例难治和复发性NHL患者,其中T细胞NHL25例,B细胞NHL55例,既往均接受过6个周期的CHOP化疗方案无缓解。现采用DICE方案对患者进行解救治疗,并对毒副反应加以评估、预防及治疗。结果:80例患者接受6个周期DICE方案化疗后,总体有效率为56.3%,完全缓解率为27.5%;T、B细胞NHL有效率分别为48.0%、60.0%,完全缓解率为16.0%、32.7%(P>0.05);经DICE方案治疗的患者出现骨髓抑制、消化系统反应、脱发以及电解质紊乱发生率增高,经过治疗均恢复,无治疗相关死亡。结论:DICE方案治疗难治和复发性NHL有效。BACKGROUND ＆ OBJECTIVE： There is no standard salvage regimen for patients with recurrent and refractory non-Hodgkin＇s lymphoma （NHL） so far. This study was to investigate the efficacy of DICE （dexamethasone, isofosfamide, cisplatin, and etoposide） regimen on recurrent and refractory NHL, and observe the adverse events. METHODS： Clinical records of 80 patients with recurrent and refractory NHL, who failed to get remission from CHOP regimen （cyclophosfamide, vincristine, and donaurubicin） and accepted DICE as a salvage regimen for 6 cycles, were reviewed. Of the 80 patients, 25 were T-cell original, and the other 55 were B-cell original. The efficacy of DICE regimen and adverse events were evaluated. RESULTS： The total response rate （RR） of these 80 patients was 56.3%. The complete remission （CR） rate was 27.5%.The total response rate was 48.0% for T-cell NHL and 60.0% for B-cell NHL. The CR rate was 16.0% for T-cell NHL and 32.7% for B-cell NHL. Myelosuppression, nausea, vomit, alopecia, and electrolytes disorder were major adverse events, and could be cured after treatment. No chemotherapy-related death occurred. CONCLUSION.. DICE regimen is effective in treating recurrent and refractory NHL.

关 键 词：非霍奇金淋巴瘤 化学疗法 DICE方案 疗效 不良反应 

分 类 号：R733.1[医药卫生—肿瘤]